Theriva Biologics, a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to lead clinical candidate VCN-01 in combination with gemcitabine and nab-paclitaxel to improve progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma. In VIRAGE, the ongoing multinational phase 2b clinical study, intravenous VCN-01 is being evaluated in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with pancreatic ductal adenocarcinoma (PDAC). Previously, the FDA granted orphan drug designation to VCN-01 for treatment of PDAC.
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva„ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases...
ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva„ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases...
- Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the...
ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) -- Theriva„ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related...
Theriva Biologics reports positive data from investigator sponsored phase 1 trial of intravitreal VCN-01 in paediatric patients with refractory retinoblastoma
“Phase 1 trial in collaboration with Sant Joan de D©u-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee“ “Safety and clinical outcomes...
“ Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft“ “ The observed synergy emphasizes VCN-01's...
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Theriva„ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related...
“ The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal...